Retractable Technologies Inc

Retractable Technologies Inc (RVP) Stock Analysis

$0.720

-0.012 (-1.64%)At close

Loading chart…
High
0.735
Open
0.700
VWAP
0.72
Vol
15.47K
Mkt Cap
32.63M
Low
0.700
Amount
11.11K
EV/EBITDA, TTM
0.00

Retractable Technologies, Inc. is engaged in the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. The Company is focused on the production of injection devices (syringes and needles). Such products are marketed under the VanishPoint, Patient Safe, and EasyPoint brands. The VanishPoint syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint needle can also be used to aspirate fluids and for blood collection. Its products are distributed by various specialty and general line distributors.

AI analysis of Retractable Technologies Inc (RVP)

hold

Retractable Technologies Inc (RVP) is currently priced at 0.73, with an RSI of 68.133 indicating it is approaching overbought territory. While the gross margin has dramatically improved to 90.85% in Q2 2026, the company also faces risks with a net loss of 4.28 million in Q1 2026 and a significant year-over-year sales decline of 13.3%.

Valuation Metrics

The current forward P/E ratio for Retractable Technologies Inc (RVP) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for RVP

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%RVP

$0.71

Scenario price

B

Base

Base · 50%RVP

$0.66

Scenario price

B

Bear

Bear · 25%RVP

$0.57

Scenario price

Events Timeline

2026-04-09 (ET)

17:50:00

Retractable Technologies Cuts Workforce by 16% to Save $2.2M

2025-04-10 (ET)

17:35:35

Retractable Technologies announces 7% workforce reduction

2025-01-14 (ET)

11:29:44

Retractable Technologies withdraws complaint in Court of International Trade

News

RVP FAQ — answered by Alphio AI

Retractable Technologies, Inc. is engaged in the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. The Company is focused on the production of injection devices (syringes and needles). Such products are marketed under the VanishPoint, Patient Safe, and EasyPoint brands. The VanishPoint syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint needle can also be used to aspirate fluids and for blood collection. Its products are distributed by various specialty and general line distributors. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Retractable Technologies Inc (RVP) is currently priced at 0.73, with an RSI of 68.133 indicating it is approaching overbought territory. While the gross margin has dramatically improved to 90.85% in Q2 2026, the company also faces risks with a net loss of 4.28 million in Q1 2026 and a significant year-over-year sales decline of 13.3%.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started